Recently we have presented the use of niacin labelled siRNA showing promise in terms of improving cellular uptake. In this latest work, we present the use of a modified C6 niacin phosphoramidite and a novel pyridoxine phosphoramidite.
Poster presented at the 2014 Annual Meeting of the Oligonucleotide Therapeutics Society, San Diego, October 2014.
bisDMT-Pyridoxine-C6-CE Phosphoramidite (2536) is now available. 5-Niacin-C6-CE Phosphoramidite (2537) will be launching soon. For further details please get in touch.
Use of 5'-Niacin-CE Phosphoramidite, 5'-Niacin-C6-CE Phosphoramidite and bisDMT-Pyridoxine-C6-CE Phosphoramidite (Patent Pending PCT/GB2015/050611) is only permitted for incorporation into oligonucleotides for private purposes, including Research Use Only (RUO) oligonucleotides, i.e. not for commercial applications. Purchase of these products from LINK allows the purchaser the right to sell an oligonucleotide modified with the products, but only for RUO by the end-user. This right only applies to product purchased from Link Technologies or a licenced vendor. For all other uses of these products, in particular commercial applications, licensing programs are available from Link Technologies Ltd. For the avoidance of doubt, a separate licence must be sought for any synthesis and commercial sale of any oligonucleotide modified with the product for any non-RUO purpose, such as, but not limited to, therapeutic and diagnostic applications. Please contact us for further details.